Erratum: CB 1 antagonism: Interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats (Psychopharmacology DOI: 10.1007/s00213-014-3575-5);CB 1 antagonism: Interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats

Psychopharmacology

Volumn 231, Issue 22, 2014, Pages 4291-4300

  Wills, Kiri L ^a   Vemuri, Kiran ^b   Kalmar, Alana ^a   Lee, Alan ^a   Limebeer, Cheryl L ^a   Makriyannis, Alexandros ^b   Parker, Linda A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Addiction; AM251; AM4113; Aversion; CB 1 antagonist; Conditioning; Dependence; FAAH; Morphine withdrawal; Naloxone; URB597

Indexed keywords

CANNABINOID 1 RECEPTOR; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

AFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MALE; RAT; SPRAGUE DAWLEY RAT; SUBSTANCE WITHDRAWAL SYNDROME;

AFFECT; ANALGESICS, OPIOID; ANIMALS; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84939882534     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3692-1     Document Type: Erratum

References (61)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16(4):411-420
2. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A (2008) Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 93:666-670
3. Bhargava HN (1976) Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-Δ9-tetrahydrocannabinol. Eur J Pharmacol 36(1):259-262
4. Bozarth MA, Wise RA (1984) Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224:516-517
5. Caille S, Parsons LH (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 18:3145-3149
6. 1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193
7. Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berlin) 135:324-332
8. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713
9. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmer ANM (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168:164-169
10. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W (2003) Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17:1723-1726
11. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3- carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313(1):352-358
12. Ford CP, Mark GP, Williams JT (2006) Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26:2788-2797
13. Frenois F, Cador M, Caillé S, Stinus L, Le Moine C (2002) Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16:1377-1389
14. Frenois F, Stinus L, Di Blasi F, Cador M, Le Moine C (2005) A specific limbic circuit underlies opiate withdrawal memories. J Neurosci 25(6):1366-1374
15. Gobbi G, Bambico FR, Manqieri R, Bortalato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620-18625
16. Gracy NK, Dankiewicz LA, Koob GF (2001) Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24:152-160
17. Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1990) Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hr postmorphine. Pharmacol Biochem Behav 36:393-399
18. Hou YY, Lu B, Li M, Liu Y, Chen J, Chi ZQ, Liu JG (2009) Involvement of actin rearrangement within the amygdala and the dorsal hippocampus in aversive memories of drug withdrawal in acute morphine-dependent rats. J Neurosci 29(39):12244-12254
19. Ishida S, Shimosaka R, Kawasaki Y, Jin C, Kitamura Y, Araki H, Sendo T, Gomita Y (2008) Involvement of the amygdala on place aversion induced by naloxone in single-dose morphine-treated rats. Yakugaku Zasshi 128(3):395-403
20. Jin C, Araki H, Nagata M, Suemaru K, Shibata K, Kawasaki H, Hamamura T, Gomita Y (2004) Withdrawal-induced c-Fos expression in the rat centromedial amygdala 24 h following a single morphine exposure. Psychopharmacology 175:428-435
21. Jin C, Araki H, Nagata M, Shimosaka R, Shibata K, Suemaru K, Kawasaki H, Gomita Y (2005) Expression of c-Fos in the rat central amygdala accompanies the acquisition but not expression of conditioned place aversion induced by withdrawal from acute morphine dependence. Behav Brain Res 161:107-112
22. Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488
23. June HL, Stitzer ML, Cone E (1995) Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin Pharmacol Ther 57:270-280
24. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana GL, Calignano A, Guistino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76-81
25. Koob GF (2009) Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 42(suppl 1):S32-S41
26. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58
27. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97-129
28. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404
29. Li Y, Liu X, Chen H, Deng H, Xiang X, Chen H, Hao W (2007) Development, extinction and reinstatement of morphine withdrawal-induced conditioned place aversion in rats. Addict Biol 12:470-477
30. Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in Δ9-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007-1014
31. Madhavan A, Bonci A, Whistler JL (2010) Opioid-induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J Neurosci 30:14029-14035
32. Maldonado R, Stinus L, Gold LH, Koob GF (1992) Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669-677
33. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29(4):225-232
34. Manwell LA, Satvat E, Lang ST, Allen CP, Leri F, Parker LA (2009) FAAH inhibitor, URB- 597, promotes extinction and CB1 antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94:154-162
35. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F (2001) Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132(8):1809-1816
36. McCallum AL, Limebeer CL, Parker LA (2010) Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine- induced conditioned floor preference and naloxone-precipitated morphine withdrawal- induced conditioned floor avoidance. Pharmacol Biochem Behav 96:496-500
37. McDonald RV, Parker LA, Siegel S (1997) Conditioned sucrose aversions produced by naloxone-precipitated withdrawal from acutely administered morphine. Pharmacol Biochem Behav 58:1003-1008
38. Meyer DR, Sparber SB (1977) Evidence of possible opiate dependence during the behavioral depressant action of a single dose of morphine. Life Sci 73:1087-1094
39. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gómez R, del Arco I, Villanúa MA, Maldonado R, Koob GF, Rodríguez de Fonseca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self- administration. J Neurosci 21:5344-5350
40. Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278:58-63
41. Parker LA, Joshi A (1998) Naloxone-precipitated morphine withdrawal induced place aversions: effects of naloxone at 24 hours postmorphine. Pharmacol Biochem Behav 61(3):331-333
42. Parker LA, Cyr JA, Santi AN, Burton PD (2002) The aversive properties of acute morphine dependence persist 48 h after a single exposure to morphine: evaluation by taste and place conditioning. Pharmacol Biochem Behav 7287-7292
43. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004) Effect of low doses of Δ9- tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 175:360-366
44. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339:173-186
45. Rubino T, Massi P, Vigano' D, Fuzio D, Parolaro D (2000) Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 66(22):2213-2219
46. Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781
47. Shoji Y, Delfs J, Williams JT (1999) Presynaptic inhibition of GABA(B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 19:2347-2355
48. Singh ME, Verty AN, McGregor IS, Mallet PE (2004) A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 1026:244-253
49. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2010) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112-122
50. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self- administration in rats. J Pharmacol Exp Ther 306:93-102
51. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005) Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30:2046-2057
52. Stinus L, Le Moal M, Koob GF (1990) Nucleus accumbens and the amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37(3):767-773
53. Trang T, Ma W, Chabot JG, Quirion R, Jhamandas K (2006) Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence. Pain 126:256-271
54. Valverde O, Tzavara E, Hanoune J, Roques BP, Maldonado R (1996) Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate Withdrawal. Eur J Neurosci 8:2671-2678
55. Vela G, Ruiz-Gayo M, Fuentes JA (1995) Anandamide decreases naloxone precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34(6):665-668
56. Watanabe T, Yamamoto R, Maeda A, Nakagawa T, Minami M, Satoh M (2002) Effects of excitotoxic lesions of the central or basolateral nucleus of the amygdala on naloxone- precipitated withdrawal-induced conditioned place aversion in morphine-dependent rats. Brain Res 958:423-428
57. Wei E, Loh HH, Way EL (1972) Brain sites of precipitated abstinence in morphine dependent rats. J. Pharmacol Exp Ther 185:108-115
58. Wei E, Loh HH, Way EL (1973) Neuroanatomical correlates of wet shake behavior in the rat. Life Sci 12(Part II):489-496
59. Xu W, Li YH, Tan BP, Luo XJ, Xiao L, Zheng XG, Yang XY, Sui N (2012) Inhibition of the acquisition of conditioned place aversion by dopaminergic lesions of the central nucleus of the amygdala in morphine-treated rats. Physiol Res 61:437-442
60. Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909:121-126
61. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A (2008) Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 19:716-723